Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hallvard Holdaas

Showing results (31-40 of 156) with videos related to

Pageof 16
Sort By:
Atherosclerosis|July 15, 2009
Comparison of predictive ability of lipoprotein components to that of traditional risk factors of coronary events in renal transplant recipientsIngar Holme, Bengt Fellstrom, Alan Jardine, et al.
Kidney International. Supplement|April 16, 2003
Why do we need a statin trial in hemodialysis patients?Bengt C Fellström, Hallvard Holdaas, Alan G Jardine
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|October 6, 2012
[Immunosuppressive drugs and the development of skin cancer after organ transplantation]Petter Gjersvik, Per Helsing, Hallvard Holdaas, et al.
Kidney International|August 30, 2014
The authors replyGeir Mjøen, Stein Hallan, Friedo W Dekker, et al.
Transplantation Direct|February 22, 2018
Immunosuppression Adherence in Stable Kidney Transplant Patients Converted From Immediate- to Prolonged-Release Tacrolimus in Clinical Practice: A Norwegian StudySadollah Abedini, Lasse Gøransson, Elinor Cockburn, et al.
Transplantation|June 23, 2009
Belatacept as immunosuppression in patient with recurrence of hemolytic uremic syndrome after renal transplantationKarsten Midtvedt, Jan Bitter, Christina Dørje, et al.
International Journal of Cardiology|August 8, 2006
The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trialsHallvard Holdaas, Christoph Wanner, Claudia Abletshauser, et al.
Renal Failure|August 25, 2006
The renal safety profile of fluvastatin: results of a pooled analysisHallvard Holdaas, Christoph Wanner, Claudia Abletshauser, et al.
Kidney International|January 5, 2019
Regarding age-calibrated glomerular filtration rateGeir Mjoen, Anna Reisæter, Anders Hartmann, et al.
Transplantation|October 5, 2013
Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients: an echocardiographic substudy of the randomized controlled CENTRAL trialKlaus Murbraech, Hallvard Holdaas, Richard Massey, et al.
Pageof 16

Showing results (31-40 of 156) with videos related to

Sort By:
Pageof 16
Atherosclerosis|July 15, 2009
Comparison of predictive ability of lipoprotein components to that of traditional risk factors of coronary events in renal transplant recipientsIngar Holme, Bengt Fellstrom, Alan Jardine, et al.
Kidney International. Supplement|April 16, 2003
Why do we need a statin trial in hemodialysis patients?Bengt C Fellström, Hallvard Holdaas, Alan G Jardine
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|October 6, 2012
[Immunosuppressive drugs and the development of skin cancer after organ transplantation]Petter Gjersvik, Per Helsing, Hallvard Holdaas, et al.
Kidney International|August 30, 2014
The authors replyGeir Mjøen, Stein Hallan, Friedo W Dekker, et al.
Transplantation Direct|February 22, 2018
Immunosuppression Adherence in Stable Kidney Transplant Patients Converted From Immediate- to Prolonged-Release Tacrolimus in Clinical Practice: A Norwegian StudySadollah Abedini, Lasse Gøransson, Elinor Cockburn, et al.
Transplantation|June 23, 2009
Belatacept as immunosuppression in patient with recurrence of hemolytic uremic syndrome after renal transplantationKarsten Midtvedt, Jan Bitter, Christina Dørje, et al.
International Journal of Cardiology|August 8, 2006
The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trialsHallvard Holdaas, Christoph Wanner, Claudia Abletshauser, et al.
Renal Failure|August 25, 2006
The renal safety profile of fluvastatin: results of a pooled analysisHallvard Holdaas, Christoph Wanner, Claudia Abletshauser, et al.
Kidney International|January 5, 2019
Regarding age-calibrated glomerular filtration rateGeir Mjoen, Anna Reisæter, Anders Hartmann, et al.
Transplantation|October 5, 2013
Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients: an echocardiographic substudy of the randomized controlled CENTRAL trialKlaus Murbraech, Hallvard Holdaas, Richard Massey, et al.
Pageof 16